OTC · Drug Manufacturers - Specialty & Generic

Genomma Lab Internacional, S.A.B. de C.V. (GNMLF) Stock

$0.86 +0.00% OTC: GNMLF Healthcare

Genomma Lab Internacional, S.A.B. de C.V., alongside its various operating units, specializes in the creation, promotion, and distribution of a wide array of over-the-counter (OTC) pharmaceutical goods and personal care items.

Valuation

MetricValue
Price$0.86
Market Cap$840.87M
P/E Ratio8.85
P/B Ratio1.21
P/S Ratio0.82
EPS (TTM)$0.10
52-Week High$1.17
52-Week Low$0.84
Dividend Yield5.81%

Financials & Margins

MetricValue
ROE14.23%
ROA6.46%
ROCE21.06%
Gross Margin62.98%
Operating Margin20.84%
Net Margin9.25%
Debt/Equity0.40
Current Ratio1.79

Annual Financials (USD)

Metric20212022202320242025
Revenue$15.5B$16.9B$16.8B$18.6B$17.5B
Operating Profit$3.0B$3.3B$3.3B$3.9B$3.8B
Net Profit$1.3B$1.4B$1.1B$1.5B$1.6B
EPS$1.30$1.40$1.15$1.53$1.65
Op Margin19.4%19.6%19.5%21.0%21.4%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$21.5B$21.7B$21.1B$23.0B$23.8B
Total Liabilities$11.5B$11.5B$11.5B$12.1B$12.7B
Cash$1.3B$1.5B$25.5B$2.3B$2.9B
Borrowings$6.0B$6.5B$108.0B$6.5B$7.6B

Latest News

Genomma Lab Internacional SAB de CV (GNMLF) Q2 2026 Earnings Call Highlights: Navigating Market ... GuruFocus.com · Jul 25, 2026 Genomma Lab Internacional Announces Results for the Second Quarter 2026 PR Newswire · Jul 23, 2026 Genomma Lab Internacional Announces Long-Term Debt Refinancing Transaction PR Newswire · Jul 22, 2026 Genomma Lab Internacional S.A.B. de C.V. Second Quarter 2026 Earnings Results Conference Call PR Newswire · Jul 6, 2026 GENOMMA LAB INTERNACIONAL ANNOUNCES SIXTEENTH DIVIDEND PAYMENT PR Newswire · Jun 29, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$1.1B$1.7B$1.6B$3.0B$1.4B
Investing Cash Flow$-1.7B$-1.1B$-544.0M$-744.0M$-1.4B
Financing Cash Flow$-78.0M$-1.5B$457.0M$-2.6B$-1.9B
Net Cash Flow$-903.0M$33.0M$190.0M$802.0M$879.0M
Free Cash Flow$278.0M$1.2B$1.4B$96.0M$838.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.30
EV / EBITDA4.46
FCF Yield10.47%
Quick Ratio1.53
Interest Coverage4.35
Return 1Y92.67%
Return 3Y1385.51%
Return 5Y—

Ownership

Insiders Held31.05%
Institutions Held32.41%
Institutions Float Held47.01%
Institutional HolderSharesReport Date
HARTFORD MUTUAL FUNDS INC/CT-The Hartford International Value Fund28,044,0522026-04-30
Fidelity Investment Trust-Fidelity International Small Cap Fund15,307,7422026-04-30
Fidelity Puritan Trust-Fidelity Low-Priced Stock Fund12,969,0142026-04-30
AIM Investment Fd.s -Invesco Emerging Markets ex-China Fd.12,721,4652026-04-30
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund10,135,6082026-04-30

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BIOGYBioGaia AB (publ) $11.00 +0.00% 33.70 $1.11B 3.82%
EXETFExtendicare Inc. $25.94 -5.02% 26.35 $2.46B 1.46%
KSPHFKissei Pharmaceutical Co., Ltd. $25.77 +0.00% 12.66 $1.07B 3.10%
LJUIFSSY Group Limited $0.40 +0.00% 14.97 $1.19B 2.50%
NWKHYNetcare Limited $7.17 +0.00% 12.89 $843.64M 7.53%

About Genomma Lab Internacional, S.A.B. de C.V.

Genomma Lab Internacional, S.A.B. de C.V., alongside its various operating units, specializes in the creation, promotion, and distribution of a wide array of over-the-counter (OTC) pharmaceutical goods and personal care items. Its operations span across Mexico and numerous international markets. The company's extensive product portfolio addresses diverse consumer needs, encompassing categories such as skincare, hair care, general health and wellness solutions, and pain management. Specific offerings include remedies for coughs and colds, digestive health aids, sexual well-being products, antiperspirants and deodorants, hand sanitizers, isotonic beverages, and shaving essentials. Beyond these, it also markets specialized pharmaceuticals such as analgesics, antifungals, and treatments for hemorrhoids. These products are brought to market under a multitude of well-known brands, including Cicatricure, Asepxia, Teatrical, Goicoechea, Sistema GB, Medicasp, Tío Nacho, Vanart, Novamil, Ultra Bengue, X-Ray, Tafirol, Alliviax, Bufferin, Next, XL-3, Genoprazol, QG5, Kaopectate, Proctan, Nikzon, Unesia, Silka Medic, lagicam, Suerox, Groomen, DiabetTX, among others. Established in 1996, Genomma Lab Internacional, S.A.B. de C.V. maintains its corporate headquarters in Mexico City, Mexico.

Genomma Lab Internacional, S.A.B. de C.V. is headquartered in MX.

Genomma Lab Internacional, S.A.B. de C.V. (GNMLF) stock trades at $0.86 with a market capitalization of $840.87M. The stock is valued at a price-to-earnings (P/E) ratio of 8.85, price-to-book of 1.21, price-to-sales of 0.82. Over the past 52 weeks the stock has ranged between $0.84 and $1.17, and currently trades 26.5% below its 52-week high. It pays a dividend yielding 5.81%.

On profitability, Genomma Lab Internacional, S.A.B. de C.V. generates a return on equity (ROE) of 14.23%, above the typical market average, return on capital employed of 21.06%, an operating margin of 20.84%, a net profit margin of 9.25%.

Official website: www.genommalab.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides